Want to see AU:CU6 full AI Analyst Report?

Clarity Pharmaceuticals Ltd. (CU6) Price & Analysis

297 Followers

CU6 Stock Chart & Stats

AU$2.35

-AU$0.09(-4.04%)

At close: Jul 28 4:00 PM EDT

AU$2.35

-AU$0.09(-4.04%)

Day’s Range― - ―

52-Week RangeAU$1.80 - AU$5.87

Previous CloseN/A

Volume1.02M

Average Volume (3M)3.27M

Market Cap

AU$884.20M

Enterprise ValueAU$1.00K

Total Cash (Recent Filing)AU$226.25M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta2.41

Next Earnings

Aug 26, 2026

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.28

Shares Outstanding373,081,240

10 Day Avg. Volume4,406,737

30 Day Avg. Volume3,266,690

Financial Highlights & Ratios

PEG Ratio-0.37

Price to Book (P/B)8.84

Price to Sales (P/S)84.33

P/FCF Ratio-14.52

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$7.01

Price Target Upside198.09% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.34

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero reported debt materially reduces interest burden and financial risk for a cash-burning clinical-stage biotech. This financial conservatism extends runway flexibility, improves solvency resilience, and enhances negotiating leverage for partnering or licensing deals over the next several quarters.

Theranostics-focused Business ModelClarity's focus on targeted radiopharmaceutical diagnostics and therapeutics aligns with durable oncology and precision-medicine trends. Specialized expertise in theranostics creates high technical barriers to entry and supports long-term partnering, licensing and commercial opportunities if clinical programs reach milestones.

High Gross Margins PotentialReported gross margins near 100% indicate attractive unit economics typical of bespoke radiopharmaceuticals; once regulatory approval and commercial scale are achieved, incremental revenues can convert to strong margins, supporting sustainable long-term profitability if revenue scaling occurs.

Bears Say

Persistent Cash BurnOperating and free cash flow have been negative every year and outflows increased in 2025, creating ongoing funding needs. Persistent cash burn forces reliance on external capital, elevates dilution risk, and can delay clinical development or commercialization absent committed partners or financing.

Widening Operating LossesSustained, deep operating losses that widened in 2025 erode equity and limit the company's ability to self-fund R&D. Continued negative profitability increases the probability of restructuring, program delays, or the need for licensing/sale of assets to preserve operations over the medium term.

Recent Revenue DeclineA roughly 12% revenue decline in 2025 interrupts prior long-run growth and raises execution risk for commercial adoption. For a development-stage company, falling revenue heightens dependence on milestone payments or partnerships and reduces visibility on when scalable revenue will materialize.

Clarity Pharmaceuticals Ltd. News

Clarity Pharmaceuticals Bolsters Cash, Manufacturing and Governance Ahead of Commercial Launch

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has provided an update. Clarity Pharmaceuticals ended the June 2026 quarter with...

4d ago

CU6

JPMorgan Ceases to Be Substantial Holder in Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has provided an update. JPMorgan Chase & Co. and its affiliates have...

27d ago

CU6

Vanguard Cuts Stake Below Substantial Holder Threshold in Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has provided an update. Vanguard Group has notified Clarity Pharmaceuticals that it...

28d ago

CU6

Clarity Pharmaceuticals Issues New Shares Following Option Exercise

The latest announcement is out from Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ). Clarity Pharmaceuticals has issued 110,000 fully...

1M ago

CU6

Clarity Pharmaceuticals Seeks ASX Quotation for Additional 110,000 Shares

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) just unveiled an announcement. Clarity Pharmaceuticals Ltd has applied for quotation on...

1M ago

CU6

Clarity’s SAR-bisPSMA data set to showcase prostate cancer advances at EANM 2026

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has shared an update. Clarity Pharmaceuticals will present new data on its...

1M ago

CU6

Clarity Pharmaceuticals marks 100-staff milestone as it builds radiopharmaceutical capabilities

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has provided an announcement. Clarity Pharmaceuticals has reached a 100-employee milestone, reflecting...

1M ago

CU6

Regal Partners exits substantial holding in Clarity Pharmaceuticals

An update from Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) is now available. Regal Partners Funds Management Pty Ltd...

1M ago

CU6

State Street Group Ceases to Be Substantial Holder in Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has shared an update. State Street Corporation and several of its asset...

1M ago

CU6

Clarity Pharmaceuticals Issues New Unquoted Options Under Employee Incentive Scheme

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) just unveiled an announcement. Clarity Pharmaceuticals has notified the market of the...

2M ago

CU6

CU6 FAQ

What was Clarity Pharmaceuticals Ltd.’s price range in the past 12 months?

Clarity Pharmaceuticals Ltd. lowest share price was AU$1.80 and its highest was AU$5.87 in the past 12 months.

What is Clarity Pharmaceuticals Ltd.’s market cap?

Clarity Pharmaceuticals Ltd.’s market cap is AU$884.20M.

When is Clarity Pharmaceuticals Ltd.’s upcoming earnings report date?

Clarity Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 22 days.

How were Clarity Pharmaceuticals Ltd.’s earnings last quarter?

Clarity Pharmaceuticals Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.153 earnings per share for the quarter, missing the consensus estimate of -AU$0.083 by -AU$0.07.

Is Clarity Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Clarity Pharmaceuticals Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Clarity Pharmaceuticals Ltd. pay dividends?

Clarity Pharmaceuticals Ltd. does not currently pay dividends.

What is Clarity Pharmaceuticals Ltd.’s EPS estimate?

Clarity Pharmaceuticals Ltd.’s EPS estimate is -0.15.

How many shares outstanding does Clarity Pharmaceuticals Ltd. have?

Clarity Pharmaceuticals Ltd. has 373,081,240 shares outstanding.

What happened to Clarity Pharmaceuticals Ltd.’s price movement after its last earnings report?

Clarity Pharmaceuticals Ltd. reported an EPS of -AU$0.153 in its last earnings report, missing expectations of -AU$0.083. Following the earnings report the stock price went up 0.278%.

Which hedge fund is a major shareholder of Clarity Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in AU:CU6

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Clarity Pharmaceuticals Ltd. Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

86.54%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Clarity Pharmaceuticals Ltd.

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.

Clarity Pharmaceuticals Ltd. (CU6) Earnings & Revenues

Historic Earnings Reports

CU6 Stock 12 Month Forecast

Average Price Target

AU$7.01

▲(198.09% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"AU$1","3":"AU$3","5":"AU$5","7":"AU$7","9":"AU$9"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$8.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.005,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$5.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3,5,7,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.12,2.603846153846154,3.0876923076923077,3.571538461538462,4.055384615384615,4.53923076923077,5.023076923076923,5.506923076923077,5.9907692307692315,6.474615384615385,6.958461538461539,7.4423076923076925,7.926153846153847,{"y":8.41,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.12,2.495769230769231,2.871538461538462,3.2473076923076922,3.623076923076923,3.998846153846154,4.374615384615384,4.750384615384615,5.126153846153846,5.501923076923077,5.877692307692308,6.253461538461538,6.629230769230769,{"y":7.005,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.12,2.3876923076923076,2.6553846153846155,2.9230769230769234,3.190769230769231,3.4584615384615383,3.726153846153846,3.993846153846154,4.2615384615384615,4.529230769230769,4.796923076923077,5.064615384615385,5.332307692307692,{"y":5.6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.94,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.49,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.71,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.08,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.39,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.32,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >